Strength

2; 10; 30 mg/5mL; mg/5mL; mg/5mL

Manufacturer

Padagis US LLC

NDC

00574110416

Classification

Generic

Dosage Form

SYRUP

Route

ORAL

Last Updated

4/22/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA205292

On Market Since

2/6/2015

Pharmacological Classes

Adrenergic alpha-Agonists
Sigma-1 Agonist
Sigma-1 Receptor Agonists
Uncompetitive N-methyl-D-aspartate Receptor Antagonist
Uncompetitive NMDA Receptor Antagonists
alpha-Adrenergic Agonist

Price History

1W

0.0%

1M

-4.5%

3M

-9.8%

6M

-16.1%

1Y

-22.1%

3Y

-9.9%

5Y

+12.1%

All

-61.4%